5/29/2012 9:45:44 AM
BEDMINSTER, N.J. and DUBLIN, Ireland, May 29, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering the pharmaceutical composition of Amarin's AMR101 based on U.S. Patent Application Serial No. 12/052,598, also known as the EPA with no DHA in a capsule application. Amarin announced on March 20, 2012, the issuance of a Notice of Allowance for claims under this application. The newly issued patent, U.S. Patent No. 8,188,146, is titled "Highly Purified Ethyl EPA and Other EPA Derivatives."
comments powered by